博奥信生物技术(南京)有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets 2024-11-18 21:50
Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference 2024-06-11 18:00
Biosion to Present Three Posters at the 2024 AACR Meeting 2024-03-21 19:00
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC) 2024-01-08 19:35
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT) 2023-07-31 17:05
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development 2023-07-05 22:05
Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody 2023-05-08 19:30
Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis 2023-04-04 20:50
Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023 2023-03-22 20:19
Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates 2022-12-13 18:00
Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board 2022-09-07 20:54
Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer 2022-08-22 13:00
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology 2022-03-29 23:00
Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer 2022-02-21 13:00
Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD 2022-01-03 18:00
1